Literature DB >> 28706919

Microbiome in chronic obstructive pulmonary disease.

Eduard Monsó1.   

Abstract

The introduction of culture-independent techniques for the microbiological analysis of respiratory samples has confirmed that the respiratory system hosts a large number of microorganisms, which include a wide range of bacteria. The regular exposure to tobacco smoke changes the microbiome in healthy smokers, first in the oropharynx, increasing the presence of a restricted number of genera which attain high relative abundance, a pattern that may be considered as dysbiosis. In chronic obstructive pulmonary disease (COPD), microbiome analyses of sputum samples have demonstrated an important decline in bacterial diversity, with a change to a restricted flora with an overrepresentation of the Proteobacteria phylum, which include most of the bacteria commonly considered as potentially pathogenic microorganisms, paralleled by a decline in the relative abundance of microorganisms part of the Firmicutes phylum. In exacerbations, specific bacteria overrepresented in microbiome analyses and potentially causal of the acute episode may not be recovered by sputum culture, while colonizing microorganisms grow easily, in spite that their relative abundance have not changed from previous stability. This situation has been described in patients showing chronic colonization by Pseudomonas aeruginosa, who suffer from exacerbations that in most cases are due to other PPMs, in spite of the persistence of positive cultures for the colonizing Pseudomonas strains. Interaction between different microorganisms can be addressed through microbiome analyses, and functional metagenomics, that describes the genomic potential of the community, has shown that, in spite that the bronchial microbiome as a whole may not change significantly, clear changes in carbohydrate metabolism, cancer, cell growth and death, transport and catabolism pathways often appear during exacerbations. These functional changes may be important because through them the resident community as a whole show its power to modify important metabolic patterns.

Entities:  

Keywords:  Chronic obstructive pulmonary disease (COPD); bronchial colonization; exacerbation; microbial interaction; proteobacteria; respiratory microbiome

Year:  2017        PMID: 28706919      PMCID: PMC5497093          DOI: 10.21037/atm.2017.04.20

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  37 in total

Review 1.  Infection in the pathogenesis and course of chronic obstructive pulmonary disease.

Authors:  Sanjay Sethi; Timothy F Murphy
Journal:  N Engl J Med       Date:  2008-11-27       Impact factor: 91.245

2.  Severity-related changes of bronchial microbiome in chronic obstructive pulmonary disease.

Authors:  Marian Garcia-Nuñez; Laura Millares; Xavier Pomares; Rafaela Ferrari; Vicente Pérez-Brocal; Miguel Gallego; Mateu Espasa; Andrés Moya; Eduard Monsó
Journal:  J Clin Microbiol       Date:  2014-09-24       Impact factor: 5.948

3.  Bacterial sputum cultures. A clinician's viewpoint.

Authors:  R E Van Scoy
Journal:  Mayo Clin Proc       Date:  1977-01       Impact factor: 7.616

4.  Bronchial microbiome, PA biofilm-forming capacity and exacerbation in severe COPD patients colonized by P. aeruginosa.

Authors:  Marian Garcia-Nuñez; Sara Marti; Carmen Puig; Vicente Perez-Brocal; Laura Millares; Salud Santos; Carmen Ardanuy; Andres Moya; Josefina Liñares; Eduard Monsó
Journal:  Future Microbiol       Date:  2017-03-24       Impact factor: 3.165

5.  Metabolic alterations to the mucosal microbiota in inflammatory bowel disease.

Authors:  Michael Davenport; Jordan Poles; Jacqueline M Leung; Martin J Wolff; Wasif M Abidi; Thomas Ullman; Lloyd Mayer; Ilseung Cho; P'ng Loke
Journal:  Inflamm Bowel Dis       Date:  2014-04       Impact factor: 5.325

6.  Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations.

Authors:  Alberto Papi; Cinzia Maria Bellettato; Fausto Braccioni; Micaela Romagnoli; Paolo Casolari; Gaetano Caramori; Leonardo M Fabbri; Sebastian L Johnston
Journal:  Am J Respir Crit Care Med       Date:  2006-02-16       Impact factor: 21.405

7.  Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis.

Authors:  James D Chalmers; Maeve P Smith; Brian J McHugh; Cathy Doherty; John R Govan; Adam T Hill
Journal:  Am J Respir Crit Care Med       Date:  2012-06-28       Impact factor: 21.405

8.  Lung microbiome dynamics in COPD exacerbations.

Authors:  Zhang Wang; Mona Bafadhel; Koirobi Haldar; Aaron Spivak; David Mayhew; Bruce E Miller; Ruth Tal-Singer; Sebastian L Johnston; Mohammadali Yavari Ramsheh; Michael R Barer; Christopher E Brightling; James R Brown
Journal:  Eur Respir J       Date:  2016-02-25       Impact factor: 16.671

9.  Assessing bacterial populations in the lung by replicate analysis of samples from the upper and lower respiratory tracts.

Authors:  Emily S Charlson; Kyle Bittinger; Jun Chen; Joshua M Diamond; Hongzhe Li; Ronald G Collman; Frederic D Bushman
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

10.  Functional Metagenomics of the Bronchial Microbiome in COPD.

Authors:  Laura Millares; Vicente Pérez-Brocal; Rafaela Ferrari; Miguel Gallego; Xavier Pomares; Marian García-Núñez; Concepción Montón; Silvia Capilla; Eduard Monsó; Andrés Moya
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

View more
  10 in total

Review 1.  Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis.

Authors:  Brielle A Parris; Hannah E O'Farrell; Kwun M Fong; Ian A Yang
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

Review 2.  [Pseudomonas aeruginosa infections in chronic obstructive pulmonary disease : Role of long-term antibiotic treatment].

Authors:  G G U Rohde; T Welte
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

3.  Potential clinical utility of multiple target quantitative polymerase chain reaction (qPCR) array to detect microbial pathogens in patients with chronic obstructive pulmonary disease (COPD).

Authors:  Hannah E O'Farrell; Janet G Shaw; Felicia Goh; Rayleen V Bowman; Kwun M Fong; Lutz Krause; Ian A Yang
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

4.  Characteristics of the sputum microbiome in COPD exacerbations and correlations between clinical indices.

Authors:  Linfan Su; Yixian Qiao; Jinmei Luo; Rong Huang; Zhiwei Li; Hongbing Zhang; Hongmei Zhao; Jing Wang; Yi Xiao
Journal:  J Transl Med       Date:  2022-02-05       Impact factor: 5.531

Review 5.  High-Density Lipoproteins: A Role in Inflammation in COPD.

Authors:  Stanislav Kotlyarov
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

6.  Global Meta-analysis of Airborne Bacterial Communities and Associations with Anthropogenic Activities.

Authors:  Xiaoqing Jiang; Chunhui Wang; Jinyuan Guo; Jiaheng Hou; Xiao Guo; Haoyu Zhang; Jie Tan; Mo Li; Xin Li; Huaiqiu Zhu
Journal:  Environ Sci Technol       Date:  2022-07-04       Impact factor: 11.357

Review 7.  The Interplay Between Immune Response and Bacterial Infection in COPD: Focus Upon Non-typeable Haemophilus influenzae.

Authors:  Yu-Ching Su; Farshid Jalalvand; John Thegerström; Kristian Riesbeck
Journal:  Front Immunol       Date:  2018-11-05       Impact factor: 7.561

8.  [Integral approach to the acute exacerbation of chronic obstructive pulmonary disease].

Authors:  J González Del Castillo; F J Candel; J de la Fuente; F Gordo; F J Martín-Sánchez; R Menéndez; A Mujal; J Barberán
Journal:  Rev Esp Quimioter       Date:  2018-10-04       Impact factor: 1.553

Review 9.  [Three keys to the appropriate choice of oral antibiotic treatment in the respiratory tract infections].

Authors:  R Menéndez; R Cantón; A García-Caballero; J Barberán
Journal:  Rev Esp Quimioter       Date:  2019-12-04       Impact factor: 1.553

10.  Compared the Microbiota Profiles between Samples from Bronchoalveolar Lavage and Endotracheal Aspirates in Severe Pneumonia: A Real-World Experience.

Authors:  Yeong-Nan Cheng; Wei-Chih Huang; Chen-Yu Wang; Pin-Kuei Fu
Journal:  J Clin Med       Date:  2022-01-10       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.